Therapeutic Areas

By integrating real-world data more deeply into the process of clinical research, life sciences stakeholders can open up new possibilities for therapeutic development and the evidence-based treatment of hematologic cancers.

Digital twins, defined as a typical demographic patient profile in a specific population, have the potential to help clinical trial design.

Porter discusses regulatory compliance, ATMP sponsors, and Philadelphia’s Cellicon Valley.

Future shows great potential for neurological language assessments in clinical trials.

Successful oncolytic virus immunotherapy clinical development requires unique features that focus on viral biology and host immune response.

Steps that investigators and sponsors can take to streamline trials and accelerate the time to market for lifesaving therapies.

Five therapeutic areas that are apt for an all-virtual approach, and that can serve as an entry point for sponsors who are hesitant yet interested in exploring the growing DCT model.

Vanessa Tassell, Vice President of Clinical Operations at Mirati Therapeutics, will discuss how some enterprises are navigating trials by incorporating strategies to expand clinical trial access to patients who need it.

Poor representation of dark skin tones in textbooks emphasizes need for change.

The diversified sources of the somatic cells call for additional oversight to prevent the introduction, transmission, and spread of communicable disease.

RWE can augment, extend, or enrich the findings from clinical trials to provide valuable evidence to support the development programs for product approvals.

Survey data shows individuals are not informed on how COVID-19 could affect their conditions.

Developing new pathways to overcome study-related challenges is key to realizing the promise of the latest gene therapies.

How partnering with a CRO that has experience in both dermatology and innovative trial approaches can help sponsors differentiate their studies and facilitate recruitment.

Thousands of trials have been halted as a consequence of the coronavirus pandemic, slowing the pace of scientific progress dramatically.

Today's reality and the hopes of tomorrow of the COVID-19 pandemic—an updated mapping of vaccines authorized by regulatory bodies and those close to it.

Though the fields of immunotherapy and cell and gene therapies have seen significant growth since April 2012, CGT clinical research remains a challenge.

Successful collaborations between Pharma/Biotech/Device industries and CROs will play a key role in an effective fight against the global COVID-19 pandemic.

Evolving technologies include modification of receptors on T cells to better target tumor microenvironments and minimize off-tumor cross-reactivity.

87% of people surveyed said they had no concerns about a decentralized approach to clinical trials.

Sangamo executives, Melita Sun Jung and Amy Pooler, discuss the future of genomic medicines for autism spectrum disorder.

Exploring the benefits of capturing and integrating molecular biomarker data within clinical trials to build foundations for data assets.

If you are an organization content with patient-centric approaches, you are behind. Today it is about patient-driven drug development.

Moe Alsumidaie sits down with Ping Yeh, CEO and co-founder of StemoniX, to discuss how MicroOrgans will transform preclinical and clinical development in challenging areas like Alzheimer’s.

Newest revelations suggest Risk Assessment Categorization Tools are now becoming therapeutic area-specific, as an oncology-based risk library is now surfacing.

Examining the unique standards and related challenges when assessing the safety and efficacy of cancer immunotherapy candidates.

The ability to diagnose cancer at earlier stages of the disease is constrained by the specificity and mechanics of traditional diagnostic methods. The growing use of liquid biopsy technology may help overcome such barriers and potentially revolutionize cancer research, patient treatment, and survivor care.

Examining the main challenges in designing and executing MS clinical trials and proposing mitigation strategies that may help alleviate these burdens.

To vie for success in the market for dermatologic therapies, companies developing biologics must navigate a series of significant challenges, including patient compliance and safety.